Logo-InveniAI.png
InveniAI and PRISM BioLab Initiate a Collaboration for the Development of Therapeutic Candidates for Treatment of Gut-Related Diseases Impacted by the Gut-Brain Axis and Inflammasome Activation Pathways
09 sept. 2020 08h10 HE | InveniAI
Partnership with Japan-based PRISM BioLab will enable the synthesis and development of proprietary therapeutic small-molecule candidates against molecular targets identified by InveniAI’s AI platform...
Logo-InveniAI.png
Tackling Tuberculosis with AI: Novel TBMeld® Platform to Transform Research in the Prevention and Treatment of Tuberculosis
31 juil. 2020 08h00 HE | InveniAI
-InveniAI announces partnership with the Mueller Health Foundation (MHF) to create a first of its kind AI-driven platform to be used for the discovery, tracking, and evaluation of 1) novel TB...
Logo-InveniAI.png
InveniAI Enters Strategic Artificial Intelligence (AI) and Machine Learning (ML) Focused Collaboration with GlaxoSmithKline Consumer Healthcare
29 juil. 2020 08h30 HE | InveniAI
Three-year strategic collaboration to leverage InveniAI’s AI- and ML-powered Platform, AlphaMeld® after a successful proof-of-value collaborationAlphaMeld® will capture consumer-specific innovation...
Logo-InveniAI.png
InveniAI Announces Strategic Partnership with TB Alliance to Advance the Development of Transformative Therapies for Tuberculosis
02 juin 2020 08h00 HE | InveniAI
GUILDFORD, Conn., June 02, 2020 (GLOBE NEWSWIRE) -- InveniAI® LLC, a global leader pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across...
Logo-InveniAI.png
InveniAI Introduces New Products to its AI-Powered Pharmaceutical Drug Discovery and Development Suite
06 nov. 2019 08h00 HE | InveniAI
GUILFORD, Conn., Nov. 06, 2019 (GLOBE NEWSWIRE) -- InveniAI® Corporation, a global leader pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation...
Logo-InveniAI.png
InveniAI Launches Suite of Products Powered by AlphaMeld™, an Artificial Intelligence Platform, to Enable Robust Decision Making for Multiple Stakeholders in the Life Sciences
17 sept. 2019 08h30 HE | InveniAI
- CIMeld™, an AlphaMeld™ powered product for competitive/business intelligence, is set to launch at PharmaCI USA 2019 - Tailored suite of products to address high value questions accelerating...
Logo-InveniAI.png
InveniAI Appoints Industry Veteran Dr. Amit Agrawal to Board of Directors and Expands its Operations into the EU
02 juil. 2019 08h31 HE | InveniAI
 Dr. Agrawal, a biopharma Strategy and R&D leader, brings scientific and technology expertise to a world-class board of directors at InveniAI. InveniAI establishes presence in Basel, Switzerland...
Logo-InveniAI.png
InveniAI to be Featured at the 2019 BIO International Convention
29 mai 2019 08h32 HE | InveniAI
GUILFORD, Conn., May 29, 2019 (GLOBE NEWSWIRE) -- InveniAI® Corporation, a global leader pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation...
Logo-InveniAI.png
Microsoft Features InveniAI in their Series, NowThis Future: "AI for Change"
26 mars 2019 07h30 HE | InveniAI
GUILFORD, Conn., March 26, 2019 (GLOBE NEWSWIRE) -- InveniAI® Corporation, a global leader pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform...
Logo-InveniAI.png
InveniAI Featured in The Guardian’s Rare Disease Campaign to Showcase how Artificial Intelligence can be Leveraged to Create Patient Solutions
01 mars 2019 09h00 HE | InveniAI
GUILFORD, Conn., March 01, 2019 (GLOBE NEWSWIRE) -- InveniAI® Corporation, a global leader in pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform...